At a glance
- Originator Roche
- Class Antirheumatics; Small molecules
- Mechanism of Action Matrix metalloproteinase 3 inhibitors; Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 09 Nov 2006 Discontinued for Osteoarthritis (unspecified route)
- 09 Nov 2006 Discontinued for Rheumatoid arthritis (unspecified route)
- 19 Nov 2001 No-Development-Reported for Osteoarthritis (Unknown route)